Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ondine Biomedical, Inc. ( (GB:OBI) ) has provided an update.
Ondine Biomedical Inc. has announced the exercise of options to subscribe for 200,000 new ordinary shares, which will be admitted to trading on AIM. This move will increase the company’s total issued share capital to 443,433,174 ordinary shares, allowing shareholders to adjust their interests accordingly.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those from multidrug-resistant organisms. The company has a range of investigational products in development, with its nasal photodisinfection system approved in several countries and undergoing clinical trials in the US.
Average Trading Volume: 141,795
Technical Sentiment Signal: Sell
Current Market Cap: £39.89M
See more insights into OBI stock on TipRanks’ Stock Analysis page.